Crinetics Pharmaceuticals is a healthcare company focused on developing innovative therapeutics for rare endocrine diseases and metabolic disorders. Its core products include drug candidates targeting conditions such as acromegaly and Cushing's syndrome. The company operates primarily in the biopharmaceutical segment, with revenue sources stemming from research and development activities, as well as potential future product sales.
The investment profile of Crinetics Pharmaceuticals is more aligned with growth investors due to its focus on developing novel therapies and the potential for significant revenue growth as products advance through clinical stages. The stock may appeal to those with a medium to long-term investment horizon, given the nature of biopharmaceutical development. Liquidity is moderate, suitable for investors with basic to advanced experience in the healthcare sector.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-07-08 | — | Hold | High volatility; strong recent performance but negative EPS. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-07-28 | UBS | Rating Downgraded | — → 85 | 83.85 |
| 2026-07-08 | Stifel Nicolaus | Rating Downgraded | — → 85 | 83.5 |
| 2026-07-08 | Evercore ISI | Rating Downgraded | — → 85 | 83.53 |
| 2026-07-07 | Jefferies | Rating Downgraded | — → 85 | 42.03 |
| 2026-07-07 | H.C. Wainwright | Rating Downgraded | — → 85 | 42.03 |
| 2026-07-07 | Robert W. Baird | Target Raised | 62 → 85 | 42.03 |
| 2026-07-02 | UBS | Update | — → 55 | 38.68 |
| 2026-06-22 | Stifel Nicolaus | Update | — → 83 | 36.06 |
| 2026-06-15 | H.C. Wainwright | Update | — → 81 | 34.47 |
| 2026-05-15 | Evercore ISI | Target Lowered | 89 → 88 | 37.71 |
| 2026-05-11 | Oppenheimer | Target Lowered | 87 → 84 | 37.795 |
| 2026-01-30 | Stifel Nicolaus | Target Raised | 75 → 84 | 52.44 |
| 2026-01-12 | Goldman Sachs | Rating Upgraded | — → 67 | 53.25 |
